Abstract
Purpose of Review
To address the latest treatments used for pityriasis versicolor and identify those that have proven to be effective in recent publications.
Recent Findings
Even though Malassezia spp. have shown resistance to antifungals, classical treatments continue to be effective, and other novelty therapies including light therapies have shown promising results in the treatment of this condition.
Summary
Pityriasis versicolor is a common superficial fungal infection of the skin. There are numerous and diverse topical and systemic therapeutic options that are successful for the treatment and prophylaxis of this mycosis. New substances that act against the fungus through other mechanisms of action different from those used until now are expected in the near future.
Similar content being viewed by others
References
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
Gaitanis G, Velegraki A, Mayser P, Bassukas ID. Skin diseases associated with Malassezia yeasts: facts and controversies. Clin Dermatol. 2013;31:455–63.
Harada K, Saito M, Sugita T, Tsuboi R. Malassezia species and their associated skin diseases. J Dermatol. 2015;42:250–7. https://doi.org/10.1111/1346-8138.12700.
Rios-Yuil JM. Pityriasis versicolor: clinical spectrum and diagnosis. Curr Fungal Infect Rep. 2016;10:121–5. https://doi.org/10.1007/s12281-016-0261-6.
Borelli D, Jacobs PH, NaIl L. Tinea versicolor: epidemiologic, clinical, and therapeutic aspects. J Am Acad Dermatol. 1991;25:300–5.
Thoma W, Krämer HJ, Mayser P. Pityriasis versicolor alba. J Eur Acad Dermatol Venereol. 2005;19(2):147–52. https://doi.org/10.1111/j.1468-3083.2004.01085.x.
Cullingham K, Hull PR. Atrophying pityriasis versicolor. CMAJ. 2014;186(10):776. https://doi.org/10.1503/cmaj.131846.
Romero-Sandoval K, Costa AA, Teixeira Sousa MG, et al. Recurrent and disseminated pityriasis versicolor: a novel clinical form consequent to Malassezia-host interaction? Med Hypotheses. 2017;109:139–44. https://doi.org/10.1016/j.mehy.2017.10.013.
Faergemann J. Management of seborrheic dermatitis and pityriasis versicolor. Am J Clin Dermatol. 2000;1:75–80. https://doi.org/10.2165/00128071-200,001,020-00001.
Isa-Isa R, Cruz AC, Arenas R, Duarte Y, Linares L, Bogaert H. Pitiriasis versicolor en niños. Estudio epidemiológico y micológico de 797 casos estudiados en la República Dominicana. Med Cutan Iber Lat Am. 2002;30(1):5–8.
Motta de Morais P, Souza Cunha MG, Moreira Frota MZ. Clinical aspects of patients with pityriasis versicolor seen at a referral center for tropical dermatology in Manaus, Amazonas, Brazil. An Bras Dermatol. 2010;85(6):797–803.
• Gupta A, Foley K. Antifungal treatment for pityriasis versicolor. J Fungi. 2015;1:13–29. https://doi.org/10.3390/jof1010013 A review and evaluation of studies conducted with azole antifungics and terbinafine in pityriasis versicolor is presented.
Helou J, Obeid G, Moutran R, Maatouk I. Pityriasis versicolor: a case of resistance to treatment. Int J Dermatol. 2014;53(2):e114–6. https://doi.org/10.1111/j.13654632.2012.05689.x.
Findley K, Oh J, Yang J, et al. Topographic diversity of fungal and bacterial communities in human skin. Nature. 2013;000:1–4. https://doi.org/10.1038/nature12171.
Jo J-H, Kennedy EA, Kong HH. Topographical and physiological differences of the skin mycobiome in health and disease. Virulence. 2017;8:324–33. https://doi.org/10.1080/21505594.2016.1249093.
Sparber F, LeibundGut-Landmann S. Host responses to Malassezia spp in the mammalian skin. Front Immunol. 2017;8:1614. https://doi.org/10.3389/fimmu.2017.01614.
Wang QM, Theelen BT, Groenewald M, Bai FY, Boekhout T. Moniliellomycetes and Malasseziomycetes, two new classes in Ustilaginomycotina. Persoonia. 2014;33:41–7. https://doi.org/10.3767/003158514X682313.
Wu G, Zhao H, Li C, et al. Genus-wide comparative genomics of Malassezia delineates its phylogeny, physiology, and niche adaptation on human skin. PLoS Genet. 2015;11(11):e1005614. https://doi.org/10.1371/journal.pgen.1005614.
•• Honnavar P, Prasad GS, Ghosh A, et al. Malassezia arunalokei sp. nov., a novel yeast species isolated from seborrhoeic dermatitis patients and healthy individuals from India. J Clin Microbiol. 2016. https://doi.org/10.1128/JCM.00683-16 This article introduces a new species of Malassezia found in human skin.
•• Cabañes FJ, Coutinho DA, Puig L, Bragulat R, Castella G. New lipid-dependent Malassezia species from parrots. Nuevas especies lipodependientes del género Malassezia procedentes de loros. Rev Iberoam Micol. 2016;33:92–9. https://doi.org/10.1016/j.riam.2016.03.003 This publication presents another novo species of Malassezia isolated in birds.
Crespo Erchiga V, Ojeda Martos A, Vera Casaño A, Crespo Erchiga A, Sanchez FF. Malassezia globosa as the causative agent of pityriasis versicolor. Br J Dermatol. 2000;143(4):799–803.
Morishita N, Sei Y, Sugita T. Molecular analysis of Malassezia microflora from patients with pityriasis versicolor. Mycopathologia. 2006;161:61–5. https://doi.org/10.1007/s11046-005-0149-4.
Prohic A, Jovovic Sadikovic T, Krupalija-Fazlic M, Kuskunovic-Vlahovljak S. Malassezia species in healthy skin and in dermatological conditions. Int J Dermatol. 2016;55:494–504.
White TC, Findley K, Dawson TL Jr, et al. Fungi on the skin: dermatophytes and Malassezia. Cold Spring Harb Perspect Med. 2014;4:a019802.
Cruz R, Vieille P, Giusiano G, Sosa MA. Pitiriasis versicolor por Malassezia pachydermatis: Caso clínico. Pityriasis versicolor caused by Malassezia pachydermatis: Clinical case. Bol Micol. 2010;25:37–4. https://doi.org/10.22370/bolmicol.2010.25.0.72.
Velegraki A, Cafarchia C, Gaitanis G, Iatta R, Boekhout T. Malassezia infections in humans and animals: pathophysiology, detection, and treatment. PLoS Pathog. 2015;11(1):e1004523. https://doi.org/10.1371/journal.ppat.1004523.
Drake LA, Dinehart SM, Farmer ER, et al. Guidelines of care for superficial mycotic infections of the skin: pityriasis (tinea) versicolor. J Am Acad Dermatol. 1996;34:287–9.
Shi TW, Zhang JA, Tang YB, et al. A randomized controlled trial of combination treatment with ketoconazole 2% cream and adapalene 0.1% gel in pityriasis versicolor. J Dermatol Treat. 2014:1–4. https://doi.org/10.3109/09546634.2014.921661.
Dias MFRG, Quaresma-Santos MVP, Bernardes-Filho F, et al. Update on therapy for superficial mycoses: review article part I. An Bras Dermatol. 2013;88(5):764–74. https://doi.org/10.1590/abd1806-4841.20131996.
Sharquie KE, Al-Hamamy HM, Noaimi AA, Al-Shawi IA. Treatment of pityriasis versicolor using 1% diclofenac gel and clotrimazole cream (comparative therapeutic study). JSSDDS. 2011;15:19–23. https://doi.org/10.1016/j.jssdds.2010.10.004.
Fernández-Vozmediano JM, Armario-Hita JC. Etiopatogenia y tratamiento de la pitiriasis versicolor. Med Clin (Barc). 2006;126:7–13.
Bamford JTM, Flores-Genuino RNS, Ray S, et al. Interventions for the treatment of pityriasis versicolor. Cochrane Database Syst Rev 2014; Issue 7. Art. No.: CD011208. https://doi.org/10.1002/14651858.CD011208.
Reeder NL, Kaplan J, Xu J, et al. Zinc pyrithione inhibits yeast growth through copper influx and inactivation of iron-sulfur proteins. Antimicrob Agents Chemother. 2011;55:5753–60. https://doi.org/10.1128/AAC.00724-11.
Saunders CW, Scheynius A, Heitman J. Malassezia fungi are specialized to live on skin and associated with dandruff, eczema, and other skin diseases. PLoS Pathog. 2012;8(6):e1002701. https://doi.org/10.1371/journal.ppat.1002701.
• Hald M, Arendrup MC, Svejgaard EL, et al. Evidence-based Danish guidelines for the treatment of Malassezia – related skin diseases. Acta Derm Venereol. 2015;95:12–9 Analysis and treatment recommendations for Malassezia infections based on evidence level.
Pérez AR. Resultados del tratamiento con yodo salicílico y ketoconazol en la pitiriasis versicolor. Rev. haban cienc méd [Internet]. 2008;7:1–10 http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S1729-519X2008000100019&lng=es.
Rivard SC. Pityriasis versicolor: avoiding pitfalls in disease diagnosis and therapy. Mil Med. 2013;178(8):904–6. https://doi.org/10.7205/MILMED-D-13-00057.
Heeres J, Meerpoel L, Lewi P. Conazoles. Molecules. 2010;15:4129–88. https://doi.org/10.3390/molecules15064129.
• Angiolella L, Carradori S, Maccallini C, Giusiano G, Supuran CT. Targeting Malassezia species for novel synthetic and natural antidandruff agents. Curr Med Chem. 2017;24:1–21. https://doi.org/10.2174/0929867324666170404110631 Article review of new treatments focused on Malassezia infections.
Vandeputte P, Ferrari S, Coste AT. Antifungal resistance and new strategies to control fungal infections. Int J Microbiol. 2012;2012(713687):26. https://doi.org/10.1155/2012/713687.
Scorzoni L, de Paula e Silva ACA, Marcos CM, et al. Antifungal therapy: new advances in the understanding and treatment of mycosis. Front Microbiol. 2017;8:36. https://doi.org/10.3389/fmicb.2017.00036.
Fuentefria AM, Pippi B, Dalla Lana DF, Donato KK, de Andrade SF. Antifungals discovery: an insight into new strategies to combat antifungal resistance. Lett Appl Microbiol. 2018;66(1):2–13. https://doi.org/10.1111/lam.12820.
•• Iatta R, Puttilli MR, Immediato D, et al. The role of drug efflux pumps in Malassezia pachydermatis and Malassezia furfur defense against azoles. Mycoses 2016; 1–5. https://doi.org/10.1111/myc.12577. This publication explains one of the resistance mechanisms Malassezia spp. anti-fungal against.
Gupta AK, Kohli Y, Li A, Faergemann J, Summerbell RC. In vitro susceptibility of the seven Malassezia species to ketoconazole, voriconazole, itraconazole and terbinafine. Br J Dermatol. 2000;142:758–65.
Cafarchia C, Iatta R, Immediato D, Puttilli R, Otranto D. Azole susceptibility of Malassezia pachydermatis and Malassezia furfur and tentative epidemiological cut-off values. Med Mycol. 2015;00:1–6. https://doi.org/10.1093/mmy/myv049.
Miranda KC, de Araujo CR, Costa CR, et al. Antifungal activities of azole agents against the Malassezia species. Int J Antimicrob Agents. 2007;29(3):281–94. https://doi.org/10.1016/j.ijantimicag.2006.09.016.
Rojas FD, Córdoba SB, Sosa MA, et al. Antifungal susceptibility testing of Malassezia yeast: comparison of two different methodologies. Mycoses. 2016:1–8. https://doi.org/10.1111/myc.12556.
Leong C, Buttafuoco A, Glatz M, Bosshard PP. Antifungal susceptibility testing of Malassezia spp. with an optimized colorimetric broth microdilution method. J Clin Microbiol. 2017;55:1883–93. https://doi.org/10.1128/JCM.00338-17.
Sepahvand A, Eliasy H, Rahimi H, et al. Phytotherapy for tinea versicolor. Int J Health Med Curr Res. 2017;2:592–9. https://doi.org/10.22301/IJHMCR.2528-3189.592.
Rhimi W, Salem IB, et al. Chemical composition, antibacterial and antifungal activities of crude Dittrichia viscosa (L.) greuter leaf extracts. Molecules. 2017;22(942):1–13. https://doi.org/10.3390/molecules22070942.
• Ianiri G, Applen Clancey S, Lee SC, Heitman J. FKBP12-dependent inhibition of calcineurin mediates immunosuppressive antifungal drug action in Malassezia. mBio. 8:e01752–17. https://doi.org/10.1128/mBio.01752-17 This study paves the use of calcineurin inhibitors as alternatives in the treatment of pityriasis versicolor.
Sepaskhah M, Sadat MS, Pakshir K, Bagheri Z. Comparative efficacy of topical application of tacrolimus and clotrimazole in the treatment of pityriasis versicolor: a single blind, randomized clinical trial. Mycoses. 2017;60(5):338–42. https://doi.org/10.1111/myc.12598.
Qiao J, Li R, Ding Y, Fang H. Photodynamic therapy in the treatment of superficial mycoses: an evidence-based evaluation. Mycopathologia. 2010;170(5):339–43. https://doi.org/10.1007/s11046-010-9325-2.
Dai T, Fuchs BB, Coleman JJ, et al. Concepts and principles of photodynamic therapy as an alternative antifungal discovery platform. Front Microbiol. 2012;3:1–16. https://doi.org/10.3389/fmicb.2012.00120.
Penjweini R, Mokmeli S, Becker K, Dodt HU, Saghafi S. Effects of UV-, visible-, near-infrared beams in three therapy resistance case studies of fungal skin infections. OPJ. 2013;3:1–10. https://doi.org/10.4236/opj.2013.37A001.
Kim YJ, Kim YC. Successful treatment of pityriasis versicolor with 5-aminolevulinic acid photodynamic therapy. Arch Dermatol. 2007;143:1218–9. https://doi.org/10.1001/archderm.143.9.1218.
Abreu L, Adriano AR, Félix Bravo B, et al. Treatment of pityriasis versicolor with photodynamic therapy. J Am Acad Dermatol 2013; 68(4):S1, AB131. https://doi.org/10.1016/j.jaad.2012.12.542
Gilaberte Y, Aspiroz C, Alejandre C, Rezusta A. Crecimiento de Malassezia en piel peritumoral tras terapia fotodinámica con metil-5-aminolevulinato para queratosis actínica y cáncer de piel no melanoma. Actas Dermosifiliogr. 2015;106:70–1.
Balevi A, Üstüner P, Kakşi SA, Özdemir M. Narrow-band UV-B phototherapy: an effective and reliable treatment alternative for extensive and recurrent pityriasis versicolor. J Dermatol Treat. 2017;9:1. https://doi.org/10.1080/09546634.2017.1364690.
Ibekwea PU, Ogunbiyib AO, Ruzickac T, Sa‘rdyc M. Quality of life determinants in secondary school students with pityriasis versicolor. J Egypt Women Dermatol Soc. 2015;12:49–54. https://doi.org/10.1097/01.EWX.0000452297.12250.87.
Author information
Authors and Affiliations
Ethics declarations
Conflict of Interest
The authors declare that they have no conflict of interests.
Human and Animal Rights and Informed Consent
There was no experiment done on human or animal subjects by any of the authors for the publication of this article.
Additional information
This article is part of the Topical Collection on Fungal Infections of Skin and Subcutaneous Tissue
Rights and permissions
About this article
Cite this article
Arce, M., Gutiérrez-Mendoza, D. Pityriasis Versicolor: Treatment Update. Curr Fungal Infect Rep 12, 195–200 (2018). https://doi.org/10.1007/s12281-018-0328-7
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12281-018-0328-7